stoxline Quote Chart Rank Option Currency Glossary
  
Enveric Biosciences, Inc. (ENVB)
0.6127  -0.019 (-2.95%)    06-21 16:00
Open: 0.6605
High: 0.69
Volume: 97,684
  
Pre. Close: 0.6313
Low: 0.6127
Market Cap: 5(M)
Technical analysis
2024-06-21 4:52:03 PM
Short term     
Mid term     
Targets 6-month :  0.95 1-year :  1.1
Resists First :  0.81 Second :  0.94
Pivot price 0.73
Supports First :  0.61 Second :  0.5
MAs MA(5) :  0.67 MA(20) :  0.74
MA(100) :  0.93 MA(250) :  1.58
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  2.7 D(3) :  9.7
RSI RSI(14): 25.5
52-week High :  3.89 Low :  0.61
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ENVB ] has closed below the lower bollinger band by 7.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ENVB ] is to continue within current trading range. It is unclear right now based on current values. 44.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 47 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.69 - 0.7 0.7 - 0.71
Low: 0.6 - 0.61 0.61 - 0.61
Close: 0.6 - 0.62 0.62 - 0.62
Company Description

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Headline News

Tue, 14 May 2024
Enveric signs deal with MindBio - Green Market Report

Wed, 08 May 2024
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License ... - Microdose Psychedelic Insights

Thu, 02 May 2024
Enveric Biosciences, Inc. (ENVB) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance

Tue, 26 Mar 2024
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year ... - Yahoo Finance

Tue, 19 Mar 2024
Enveric Biosciences Explores Joint Disease Treatment Licensing - TipRanks

Tue, 19 Mar 2024
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 8 (M)
Shares Float 7 (M)
Held by Insiders 3.4 (%)
Held by Institutions 5.8 (%)
Shares Short 81 (K)
Shares Short P.Month 255 (K)
Stock Financials
EPS -6.39
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.7
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -86.2 %
Return on Equity (ttm) -197.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.08
Qtrly Earnings Growth 0 %
Operating Cash Flow -14 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -0.1
PEG Ratio 0
Price to Book value 0.86
Price to Sales 0
Price to Cash Flow -0.34
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android